查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1860231

婦科癌症藥物市場按最終用戶、分銷管道、給藥途徑、藥物類別和癌症類型分類－2025-2032年全球預測

Gynecological Cancer Drugs Market by End User, Distribution Channel, Administration Route, Drug Class, Cancer Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，婦科癌症治療市場將成長至 266.3 億美元，複合年成長率為 12.53%。

關鍵市場統計數據
基準年 2024 103.5億美元
預計年份：2025年 116.3億美元
預測年份 2032 266.3億美元
複合年成長率 (%) 12.53%

權威的導論概述了婦科腫瘤治療領域不斷變化的格局、關鍵的臨床挑戰、創新動力以及相關人員的期望。

當今婦科腫瘤治療領域的特點是科學創新日新月異、監管重點不斷變化以及醫療服務模式的演進，這些都影響著治療方案的研發、採購和實施。標靶治療、免疫腫瘤藥物以及更人性化的劑型等方面的最新進展正在重塑臨床決策。同時，醫療系統和支付方越來越重視治療價值、真實世界的治療效果以及公平的醫療服務取得。在此背景下，從臨床團隊到供應鏈管理人員的相關人員必須在臨床療效、營運可行性和報銷限制之間取得平衡。

分析重塑婦科癌症藥物研發、商業策略、監管路徑和臨床應用的變革性轉變

婦科腫瘤領域的變革性變化源自於技術、臨床和商業性趨勢的融合，這些趨勢共同重塑了研發重點和醫療服務模式。精準醫療正從概念走向核心實踐，基因組分析和伴隨診斷指導著標靶治療和PARP抑制劑的選擇，並重新定義了臨床試驗設計和標籤策略。同時，免疫療法的研究成果正被轉化為聯合治療和維持治療方案，這需要進行長期安全性監測並採用新的終點指標。這些科學進步促使申辦方進行綜合研發項目，以滿足監管證據要求和真實世界療效指標。

2025年美國關稅的累積影響：對婦科腫瘤供應鏈、藥品價格、臨床應用和研究的連鎖反應

2025年美國關稅調整將為婦科腫瘤治療領域帶來許多複雜挑戰，影響上游生產投入、跨境物流以及進口活性藥物成分和醫療設備的經濟效益。這些累積影響將波及供應商談判、組件採購決策和緊急庫存政策。為應對這些挑戰，製造商正在評估替代供應商，探索區域性生產方案，並制定本地化的包裝和標籤策略，以減輕關稅帶來的成本負擔，同時確保產品品質和合規性。

細分市場觀點：識別終端使用者環境、通路、給藥途徑、藥物類別和癌症類型對藥物取得和使用的影響

細分市場的趨勢揭示了臨床和商業職能部門在需求、應用和採購方面的不同促進因素。基於終端用戶細分，專科腫瘤診所和門診診所往往優先考慮諮詢時間短、可口服給藥且患者支持服務更完善的治療方法。同時，公立和私立醫院則傾向於優先考慮住院患者的耐受性證據以及輸液治療方法的可近性。此外，專科護理中心作為創新中心，往往是標靶治療和聯合通訊協定早期應用的重點，從而影響當地的轉診模式以及與支付方的討論。

美洲、歐洲、中東和非洲以及亞太地區的關鍵區域趨勢將影響准入路線、監管立場和商業策略。

區域性洞察凸顯了影響婦科腫瘤藥物生命週期的不同監管、臨床和商業環境。在美洲，多樣化的支付模式和對創新報銷機制的高度重視，推動了高成本療法的適應性定價和按療效付費合約的實施；同時，臨床網路和專科腫瘤中心也促進了新型治療方法的快速應用。跨境生產和分銷結構也十分普遍，需要精心協調監管和物流，以確保供應的連續性。

公司層面的策略要務是協調研發、生產夥伴關係和商業能力，以確保臨床應用和業務永續營運。

在企業層面，研發、供應鏈和商業營運的重點在於使其與不斷變化的臨床需求和支付方的期望保持一致。領先的製藥和生物技術公司正在投資於整合分子診斷、真實世界數據和患者報告數據的證據平台，以加強核准申報和上市後提案主張。同時，創新開發商與契約製造組織 (CMO) 和區域生產商之間的策略合作夥伴關係也日益普遍，旨在降低供應風險並加速在地化上市。

為產業領導者提供切實可行的策略建議，重點在於證據產生、供應鏈多元化、分銷最佳化和協作准入模式。

為了保持其在婦科腫瘤領域的優勢，產業領導者應優先考慮整合策略。首先，他們應透過投資於超越關鍵性試驗的實用證據生成項目，滿足支付方和臨床醫生的資訊需求，這些項目應涵蓋真實世界療效、患者報告結局和衛生經濟學模型。這將有助於建立引人注目的價值提案，從而支持藥物獲得優先上市資格並實現持續應用。

採用穩健的混合調查方法，整合臨床證據、監管審查、專家訪談和供應鏈情境分析，為策略決策提供支援。

本分析的調查方法整合了同行評審的臨床文獻、監管指南、專家訪談和最佳實踐，為相關人員建立了一個全面而實用的基礎。臨床見解源自於近期臨床試驗、指引更新和治療層級發展的系統性回顧，而監管分析則納入了與腫瘤藥物和伴隨診斷相關的最新政策聲明和核准途徑。為了使研究結果與實際營運限制和決策標準相符，研究人員也訪問了腫瘤科醫師、醫院處方集管理人員、供應鏈負責人和支付方代表。

總之，我們強調，創新、可及性和運作韌性必須協調一致，才能在整個婦科腫瘤治療過程中實現患者獲益。

總體而言，婦科腫瘤領域正經歷持續的策略調整階段，其驅動力包括科學創新、支付方審查以及營運複雜性。標靶治療和免疫療法的進步有望顯著改善眾多患者的治療效果，但實現這一目標需要嚴謹的證據、靈活的供應鏈以及能夠適應不同醫療環境的商業模式。隨著關稅壓力和區域監管趨勢持續影響成本結構和產品上市順序，相關人員必須採取靈活的策略，強調韌性、協作和以病人為中心的醫療服務。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • PARP抑制劑合併免疫療法在卵巢癌一線治療的臨床應用
  • 擴大靶向葉酸受體α的抗體藥物複合體在晚期子宮頸癌的應用
  • 口服選擇性雌激素受體穩壓器（SERDRs）的出現，為子宮內膜癌的個人化治療提供了可能。
  • 真實世界數據支持在復發性卵巢癌患者中Bevacizumab維持治療再挑戰策略
  • 用於早期檢測外陰部和陰道惡性腫瘤的預測性生物標記開發進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按最終用戶分類的婦科癌症藥物市場

  • 診所
    • 腫瘤診所
    • 門診部
  • 醫院
    • 私立醫院
    • 公立醫院
  • 專業醫療中心

9. 婦科癌症藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

10. 婦科癌症藥物市場依給藥途徑分類

  • 腹腔內給藥
  • 靜脈注射
    • Bolus
    • 靜脈注射
  • 口服
    • 膠囊
    • 藥片

第11章 婦科癌症藥物市場（依藥物類別分類）

  • 化療藥物
    • 烷化劑
    • 鉑化合物
    • 紫杉烷類
  • 荷爾蒙療法
    • 抗雌激素
    • Aromatase抑制劑
  • 免疫療法
    • 查核點抑制劑
    • 疫苗
  • 標靶治療
    • 血管新生抑制劑
    • PARP抑制劑
    • 蛋白酪氨酸激酶抑制劑

第12章 婦科癌症藥物市場（依癌症類型分類）

  • 子宮頸癌
  • 子宮內膜癌
  • 卵巢癌
  • 外陰癌

第13章 婦科癌症藥物市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 婦科腫瘤藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國婦科癌症藥物市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Clovis Oncology, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Johnson & Johnson
    • Eisai Co., Ltd
    • Amgen Inc.
Product Code: MRR-DD0700E81D10

The Gynecological Cancer Drugs Market is projected to grow by USD 26.63 billion at a CAGR of 12.53% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.35 billion
Estimated Year [2025] USD 11.63 billion
Forecast Year [2032] USD 26.63 billion
CAGR (%) 12.53%

Authoritative introduction outlining the shifting gynecological oncology therapeutic landscape, clinical imperatives, innovation momentum, and stakeholder expectations

The contemporary landscape of gynecological oncology therapeutics is characterized by rapid scientific innovation, shifting regulatory priorities, and evolving care delivery models that collectively influence how treatments are developed, procured, and administered. Recent advances in targeted therapies, immuno-oncology agents, and more patient-friendly administration formats are reframing clinical decision-making, while health systems and payers increasingly emphasize value, real-world outcomes, and equitable access. Against this backdrop, stakeholders from clinical teams to supply chain managers must reconcile clinical efficacy with operational feasibility and reimbursement constraints.

In addition, patient expectations and advocacy have become central to the adoption curve for new treatments, prompting manufacturers and providers to invest in clearer evidence packages and patient support programs. As regulatory agencies refine accelerated pathways and post-market evidence requirements, sponsors must balance speed-to-market with robust safety and effectiveness data. Therefore, a holistic introduction to this environment clarifies the intersecting forces that will determine which therapies succeed in routine practice, how care pathways will be organized, and what capabilities institutions must develop to remain competitive and patient-centric.

Analysis of transformative shifts reshaping gynecological cancer drug development, commercial strategies, regulatory pathways, and clinical adoption

Transformative shifts in the gynecological oncology arena are driven by converging technological, clinical, and commercial trends that together alter development priorities and care delivery. Precision medicine has moved from concept to central practice, with genomic profiling and companion diagnostics guiding the selection of targeted therapies and PARP inhibitors, thereby redefining trial design and labeling strategies. Concurrently, immunotherapy experiences are informing combination regimens and maintenance approaches, which necessitate longer-term safety monitoring and novel endpoints. These scientific advances compel sponsors to pursue integrated development programs that anticipate regulatory evidence demands and real-world performance metrics.

On the commercial front, distribution strategies and patient access models are evolving to accommodate oral therapies and outpatient administration, reducing inpatient burden but increasing the complexity of adherence management and reimbursement navigation. Moreover, care settings such as specialty centers and oncology-focused clinics are amplifying their role in early adoption, while hospitals remain pivotal for complex infusions and inpatient care. Finally, manufacturers and service providers are rethinking supply chains and risk mitigation in response to geopolitical shifts and procurement reforms, leading to greater emphasis on resilience, multiple sourcing strategies, and digital tracking technologies. Together, these transformative shifts require coordinated action across R&D, medical affairs, market access, and supply-chain operations to translate innovation into measurable patient benefit.

Cumulative effects of United States tariffs in 2025 on supply chains, drug pricing, clinical access, and research activity within the gynecological oncology sector

United States tariff adjustments in 2025 introduce a consequential layer of complexity for gynecological oncology therapeutics, affecting upstream manufacturing inputs, cross-border logistics, and the economics of imported active pharmaceutical ingredients and devices. The cumulative effects reverberate through supplier negotiations, component sourcing decisions, and contingency stock policies. In response, manufacturers are assessing alternative suppliers, regional manufacturing options, and localized packaging and labeling strategies to mitigate tariff-driven cost exposure while preserving quality and regulatory compliance.

Patient access and provider procurement are also affected, since higher landed costs can translate into greater pressure on hospital formularies and distribution channels. Payers and procurement leads may intensify scrutiny of price-per-outcome and favor therapies with clearer value propositions or lower administration burdens. Additionally, clinical trial operations that depend on international supply lines for investigational products may face delays or increased overhead, prompting sponsors to pre-position inventory or qualify secondary suppliers. Policymakers and industry associations are likely to convene stakeholder dialogues to seek exemptions, provide clarifications, or design phased implementation measures that preserve access for essential oncology therapies. Overall, these tariff dynamics accelerate strategic shifts toward supply-chain diversification, onshoring where feasible, and enhanced collaboration between manufacturers and health systems to safeguard continuity of care.

Segmentation-focused perspective revealing how end-user settings, distribution channels, administration routes, drug classes, and cancer types influence adoption and procurement

Segment-specific dynamics reveal differentiated drivers of demand, adoption, and procurement across clinical and commercial functions. Based on end-user segmentation, clinics-distinguished between oncology-focused clinics and outpatient clinics-frequently prioritize therapies that enable shorter visits, oral administration, and robust patient support services, while hospitals, whether private or public, tend to emphasize evidence of inpatient tolerability and the availability of infusion-based regimens. Specialty centers, for their part, act as innovation hubs where early adoption of targeted therapies and combination protocols is often concentrated, influencing regional referral patterns and payer discussions.

When viewed through distribution channels, hospital pharmacies remain essential for infusion and inpatient therapies, online pharmacies are gaining traction for oral regimens and continuity-of-care supply, and retail pharmacies continue to serve as accessible touchpoints for maintenance therapies and supportive-care medications. Administration routes further refine adoption logic: intraperitoneal and intravenous options typically necessitate institutional infrastructure and nursing capacity, with intravenous treatments subdivided into bolus and infusion approaches that impose different scheduling and monitoring requirements; oral therapies, available as capsules or tablets, shift adherence and monitoring responsibilities towards outpatient care teams and digital adherence solutions.

Drug-class segmentation defines clinical positioning and lifecycle strategies. Chemotherapy agents, including alkylating agents, platinum compounds, and taxanes, remain central to many regimens but are increasingly complemented or replaced by hormonal therapies such as anti-estrogens and aromatase inhibitors for selected indications. Immunotherapy approaches-checkpoint inhibitors and therapeutic vaccines-introduce new safety and combination considerations, while targeted therapies such as angiogenesis inhibitors, PARP inhibitors, and tyrosine kinase inhibitors demand molecular diagnostics and refined patient selection. Finally, cancer-type segmentation across cervical, endometrial, ovarian, and vulvar cancers shapes clinical trial design, reimbursement narratives, and advocacy priorities, since each indication carries distinct natural history, screening pathways, and survivorship concerns. Taken together, these segmentation lenses guide tailored commercial models, clinical-support programs, and evidence-generation priorities that align with the operational realities of each channel and care setting.

Key regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access pathways, regulatory positioning, and commercial strategy

Regional insights highlight distinct regulatory, clinical, and commercial environments that influence the lifecycle of gynecological oncology therapeutics. In the Americas, diverse payer models and a strong emphasis on innovative reimbursement mechanisms have encouraged adaptive pricing arrangements and outcomes-based contracting for high-cost therapies, while clinical networks and oncology centers of excellence drive rapid diffusion of new regimens. Cross-border manufacturing and distribution arrangements are also prevalent, necessitating careful regulatory harmonization and logistical coordination to ensure supply continuity.

Europe, the Middle East & Africa present a complex mosaic where centralized regulatory frameworks coexist with fragmented reimbursement rules across jurisdictions, prompting manufacturers to tailor submission strategies and real-world evidence plans region by region. In many countries within these regions, budget-constrained health systems prioritize cost-effectiveness and comparative effectiveness evidence, and public hospitals play a dominant role in high-intensity therapies. Additionally, access disparities persist across urban and rural areas, driving targeted access programs and collaborations with local health authorities.

Asia-Pacific is characterized by rapidly expanding clinical research capacity, growing domestic manufacturing capabilities, and heterogeneous payer landscapes that range from single-payer systems to private insurance models. Several markets in this region are accelerating regulatory reviews for oncology innovations and adopting digital health tools to support decentralized care and adherence monitoring. These regional differences collectively shape global launch sequencing, evidence-generation priorities, and partnership models that align with local clinical practice, procurement modalities, and patient-access imperatives.

Strategic company-level imperatives for aligning R&D, manufacturing partnerships, and commercial capabilities to secure clinical adoption and operational resilience

Company-level dynamics emphasize the need for firms to align R&D, supply chain, and commercial operations with evolving clinical needs and payer expectations. Leading pharmaceutical and biotech organizations are investing in integrated evidence platforms that combine molecular diagnostics, real-world outcomes, and patient-reported data to strengthen submissions and post-market value propositions. At the same time, strategic partnerships between innovative developers and contract manufacturing organizations or regional producers are becoming more common to mitigate supply risk and accelerate localized launches.

Commercially, firms are differentiating through service-oriented offerings such as patient-support programs, adherence solutions, and bundled care arrangements that reduce friction for clinicians and patients. Business development activity is concentrated on acquiring complementary portfolios-particularly targeted therapies, PARP inhibitors, and companion diagnostics-that can be rapidly positioned within existing oncology pathways. Additionally, some companies are experimenting with innovative contracting models and tiered pricing to preserve access across diverse payers while safeguarding long-term revenue sustainability. Operationally, investment in digital supply-chain visibility and serialization is increasingly seen as essential to maintain product integrity and comply with varied regional regulatory requirements. Collectively, these company insights underscore the importance of cross-functional alignment to convert scientific advances into durable clinical and commercial success.

Actionable strategic recommendations for industry leaders focused on evidence generation, supply-chain diversification, distribution tailoring, and collaborative access models

Industry leaders should prioritize integrated strategies that combine evidence generation, supply-chain resilience, and differentiated commercial models to stay ahead in gynecological oncology. First, invest in pragmatic evidence-generation programs that extend beyond pivotal trials to include real-world effectiveness, patient-reported outcomes, and health economic modeling to address payer and clinician information needs. By doing so, organizations can build compelling value propositions that support favorable formulary placement and durable uptake.

Second, diversify supply chains and pursue regional manufacturing options where feasible to reduce exposure to tariff and logistical shocks. Complementary to this, adopt advanced forecasting and inventory strategies that balance patient access with cost efficiency. Third, tailor distribution and patient-support models to administration routes and care settings: prioritize digital adherence tools and home-delivery solutions for oral therapies, while ensuring institutional readiness and training for complex infusion protocols. Fourth, cultivate strategic partnerships with diagnostics providers, academic centers, and advocacy groups to accelerate biomarker-driven adoption and to co-create patient-centric programs. Finally, embed flexible commercial contracting approaches, including outcomes-based arrangements and risk-sharing, to align stakeholder incentives and sustain access across heterogeneous payer environments. Taken together, these recommendations will help industry leaders translate scientific innovation into accessible, high-quality care for patients with gynecological cancers.

Robust mixed-methods research approach synthesizing clinical evidence, regulatory review, expert interviews, and supply-chain scenario analysis to inform strategic decisions

The research methodology underlying this analysis synthesizes peer-reviewed clinical literature, regulatory guidance, expert interviews, and operational best practices to create a comprehensive and pragmatic foundation for stakeholders. Clinical insights derive from a structured review of recent trials, guideline updates, and therapeutic class developments, while regulatory analysis incorporates recent policy statements and approval pathways relevant to oncology agents and companion diagnostics. Interviews with oncologists, hospital formulary managers, supply-chain leaders, and payer representatives were conducted to ground findings in real-world operational constraints and decision criteria.

Additionally, supply-chain and tariff impact assessments combine publicly available trade policy information with scenario-based operational modeling to identify likely stress points and mitigation pathways. Commercial and access perspectives were informed by case studies of recent launches and contracting innovations, with attention to administration route implications and channel readiness. Throughout, the methodology emphasized triangulation across data sources and stakeholder perspectives to ensure balanced, actionable insights that support both strategic planning and near-term operational decisions.

Concluding synthesis articulating how innovation, access, and operational resilience must be coordinated to realize patient benefits across gynecological oncology care pathways

In closing, the gynecological oncology therapeutics landscape is entering a sustained period of strategic realignment driven by scientific innovation, payer scrutiny, and operational complexity. Advances in targeted and immune-based therapies promise meaningful gains in outcomes for many patients, but realizing that promise requires rigorous evidence, adaptable supply chains, and commercial models aligned with diverse care settings. As tariff pressures and regional regulatory dynamics continue to influence cost structures and launch sequencing, stakeholders must adopt flexible strategies that emphasize resilience, collaboration, and patient-centered delivery.

Ultimately, organizations that integrate robust real-world evidence programs, diversify manufacturing and distribution, and deploy tailored access and adherence solutions will be best positioned to translate novel therapies into improved patient care. By focusing on cross-functional alignment and proactive stakeholder engagement, sponsors, providers, and payers can jointly optimize treatment pathways, improve access, and sustain innovation within gynecological oncology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical integration of PARP inhibitors with immunotherapy in front-line ovarian cancer management
  • 5.2. Expansion of antibody-drug conjugates targeting folate receptor alpha in advanced cervical cancer
  • 5.3. Emergence of oral selective estrogen receptor downregulators for personalized endometrial carcinoma therapy
  • 5.4. Real-world evidence supporting maintenance bevacizumab retreatment strategies in recurrent ovarian cancer patients
  • 5.5. Advances in predictive biomarker development for early detection of vulvar and vaginal malignancies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gynecological Cancer Drugs Market, by End User

  • 8.1. Clinics
    • 8.1.1. Oncology Clinics
    • 8.1.2. Outpatient Clinics
  • 8.2. Hospitals
    • 8.2.1. Private Hospitals
    • 8.2.2. Public Hospitals
  • 8.3. Specialty Centers

9. Gynecological Cancer Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Gynecological Cancer Drugs Market, by Administration Route

  • 10.1. Intraperitoneal
  • 10.2. Intravenous
    • 10.2.1. Bolus
    • 10.2.2. Infusion
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Tablet

11. Gynecological Cancer Drugs Market, by Drug Class

  • 11.1. Chemotherapy Agents
    • 11.1.1. Alkylating Agents
    • 11.1.2. Platinum Compounds
    • 11.1.3. Taxanes
  • 11.2. Hormonal Therapy
    • 11.2.1. Anti-Estrogens
    • 11.2.2. Aromatase Inhibitors
  • 11.3. Immunotherapy
    • 11.3.1. Checkpoint Inhibitors
    • 11.3.2. Vaccines
  • 11.4. Targeted Therapy
    • 11.4.1. Angiogenesis Inhibitors
    • 11.4.2. PARP Inhibitors
    • 11.4.3. Tyrosine Kinase Inhibitors

12. Gynecological Cancer Drugs Market, by Cancer Type

  • 12.1. Cervical Cancer
  • 12.2. Endometrial Cancer
  • 12.3. Ovarian Cancer
  • 12.4. Vulvar Cancer

13. Gynecological Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gynecological Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gynecological Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. AstraZeneca PLC
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. GlaxoSmithKline plc
    • 16.3.5. Clovis Oncology, Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Novartis AG
    • 16.3.8. Johnson & Johnson
    • 16.3.9. Eisai Co., Ltd
    • 16.3.10. Amgen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA GYNECOLO